NCT03740880 is a NA clinical trial of Dual trigger in the Number of Mature Oocytes, sponsored by ART Fertility Clinics LLC.

Who is sponsoring NCT03740880?

NCT03740880 is sponsored by ART Fertility Clinics LLC.

What drugs are being tested in NCT03740880?

Interventions in NCT03740880: Dual trigger.

What condition does NCT03740880 study?

NCT03740880 studies the Number of Mature Oocytes.

Is NCT03740880 still recruiting?

NCT03740880 is currently terminated. Last updated 4 March 2022.

Last reviewed 2022-03-04 · How we verify

NCT03740880

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trigger Time in Advanced Maternal Age Patients With Low AMH

Terminated NA Last updated 4 March 2022

What this trial tests

NA trial testing Dual trigger in the Number of Mature Oocytes in 1 participant. Terminated before completion.

Timeline

7 January 2019

Primary endpoint
12 March 2020

30 March 2020

Quick facts

Lead sponsor	ART Fertility Clinics LLC
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	1
Start date	7 January 2019
Primary completion	12 March 2020
Estimated completion	30 March 2020
Sites	1 location across United Arab Emirates

Drugs / interventions tested

Dual trigger — full drug profile →

Conditions studied

the Number of Mature Oocytes — all drugs for the Number of Mature Oocytes →

Sponsor

ART Fertility Clinics LLC

Who can join

Adults 40 to 48, female only, with the Number of Mature Oocytes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators want to verify if advanced maternal age patients with a low Anti-Müllerian hormone (AMH) level may benefit from an early trigger time (compared to a late trigger).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Dual trigger

Trials testing the same drug.

NCT04224818 — Dual Trigger in the Final Oocyte Maturation in Poor Ovarian Responders · Phase 3 · completed

Other ART Fertility Clinics LLC trials

Trials by the same sponsor.

NCT07270250 — Impact of Dry vs Humidified Culture Conditions on Blastocyst Development and Aneuploidy: A Time-lapse Sibling Oocyte Stu · NA · not yet recruiting
NCT06879002 — Comparing IVF/ICSI Cycle Outcomes of Post Ovulation Ovarian Stimulation Protocol With Elonva Without GnRH Antagonist to · not yet recruiting
NCT07093619 — Evaluating the Utility of Implementing Microfluids for Sperm Preparation Compared to Conventional Method of Density Grad · NA · recruiting
NCT06732843 — Does Recombinant FSH (rFSH, i.g. Gonal F®) as Compared to Human Menopausal Gonadotrophin (hMG) Affect Telomere Length of · recruiting
NCT07014267 — Virtual Reality for Mindfulness and Anxiety Reduction in Fertility Procedures · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03740880 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ART Fertility Clinics LLC
Last refreshed: 4 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03740880.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing